Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReVoGlio: Vortioxetine for Newly Diagnosed Glioblastoma
NCT07284628Phase 2Recruiting
- Sponsor
- University of Zurich
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vortioxetine in glioblastoma (GBM), sponsored by University of Zurich. Primary endpoint: Progression-free survival at 6 months. Started Jun 2026; status: recruiting.
02
Drugs
vortioxetine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07284628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284628.